Efficacy and safety of CFTR modulators in patients with interstitial lung disease caused by ABCA3 transporter deficiency

Lignende værker

• CFTR Modulators in People with Cystic Fibrosis: Real-World Evidence in France
  af: Lucile Regard, et al.
  Udgivet: (2022-05-01)
• Elexacaftor-tezacaftor-ivacaftor in people with cystic fibrosis harbouring two CFTR Class I variants: real-world data from the French compassionate programmeResearch in context
  af: Pierre-Régis Burgel, et al.
  Udgivet: (2025-10-01)
• Cystic fibrosis-related diabetes in the era of modern treatment using CFTR modulators in pediatric patients—a systematic review
  af: Anna Pietrzykowska, et al.
  Udgivet: (2025-11-01)
• Progress of personalized medicine of cystic fibrosis in the times of efficient CFTR modulators
  af: Burkhard Tümmler, et al.
  Udgivet: (2025-05-01)
• Use of elexacaftor/tezacaftor/ivacaftor leads to changes in detection frequencies of Staphylococcus aureus and Pseudomonas aeruginosa dependent on age and lung function in people with cystic fibrosis
  af: Anna-Maria Dittrich, et al.
  Udgivet: (2024-02-01)